Last updated: July 6, 2026
Executive summary
OSI Pharmaceuticals, LLC v. Zydus Pharmaceuticals (USA) Inc., 1:19-cv-00741, is a Hatch-Waxman (Orange Book) patent litigation initiated in 2019 by OSI Pharmaceuticals against Zydus. The case is procedurally centered on infringement and validity challenges tied to a generic (ANDA) or proposed generic entry. The public record available under the docket identifier supports that the matter is patent-centric, not a regulatory merits appeal, and it is governed by the 35 U.S.C. §§ 271(e)(2) and 282 framework typically used for Paragraph IV disputes. A litigation outcome analysis, including which patents were asserted and which were upheld or dismissed, cannot be produced from the information provided here.
What happened in OSI Pharmaceuticals, LLC v. Zydus Pharmaceuticals (USA) Inc. 1:19-cv-00741?
Short answer: This is an infringement action filed by OSI against Zydus under the Hatch-Waxman structure, with the core dispute arising from Zydus’ FDA submission and associated Paragraph IV certifications against Orange Book-listed patents.
What was OSI’s legal theory?
The complaint would align with standard Paragraph IV pleadings, typically asserting that Zydus’ ANDA (or ANDA-adjacent proposed product) would infringe specified Orange Book patents under 35 U.S.C. § 271(e)(2), and that the asserted patents were not invalid and not unenforceable.
What was Zydus’ typical litigation posture?
Paragraph IV defendants typically respond with combinations of:
- non-infringement,
- invalidity (anticipation/obviousness and sometimes statutory categories),
- unenforceability defenses (including inequitable conduct) if pleaded.
Which patents were asserted in 1:19-cv-00741?
Short answer: Not determinable from the docket identifier alone.
How to identify asserted patents from the filings
In federal Hatch-Waxman cases, the asserted patent list is contained in:
- the complaint (often in an infringement count list or “List of patents” section),
- the parties’ Rule 26 disclosures and scheduling order,
- claim charts attached or referenced during early motion practice.
How many patents were litigated?
Not determinable from the information provided.
What did the court decide in OSI v. Zydus?
Short answer: Not determinable from the information provided.
Claim construction and early motion outcomes
In patent cases, early dispositive decisions commonly include:
- claim construction (Markman),
- summary judgment on invalidity/non-infringement,
- motion to dismiss (rare after service in Paragraph IV),
- settlement or stipulated dismissal.
No ruling dates, stipulations, or dispositive holdings are provided here, so outcomes cannot be summarized accurately.
Did the case settle? What was the settlement effect on generic entry?
Short answer: Not determinable from the information provided.
Settlement can change exclusivity timing and entry dates
When settlements occur in Hatch-Waxman matters, they often include:
- “Agreed Design” product changes,
- market entry dates,
- covenants not to sue,
- monetary consideration.
No settlement agreement terms or entry-date impacts are provided here, so litigation effect cannot be quantified.
What is the Orange Book status tied to this litigation?
Short answer: Not determinable from the information provided.
Orange Book linkage drives the patent list
For Paragraph IV cases, the Orange Book provides:
- patent numbers and expiration dates,
- patent types (drug substance, drug product, method of use),
- FDA approval identifiers tied to the NDA.
No Orange Book listing details or patent identifiers are included in the information provided, so the specific status cannot be stated.
When does exclusivity or patent protection expire for the drug at issue?
Short answer: Not determinable from the information provided.
How patent and exclusivity timelines typically structure risk
In Hatch-Waxman, the generic entry risk is a function of:
- the latest expiration among asserted patents,
- exclusivity periods (if any),
- regulatory triggers like 180-day exclusivity for first filers,
- design-around workability.
No asserted patent expiration dates are available from the provided input.
How strong is OSI’s patent estate based on this litigation?
Short answer: Not determinable from the information provided.
Patent strength indicators used in litigation analysis
In determining “strength,” analysts look for:
- infringement findings,
- sustained validity across claim construction and summary judgment,
- survival of key claims through dispositive motion practice,
- appeal results, if any.
No such litigation outcomes or patent-level rulings are provided here.
What generic entry risks existed for Zydus after filing 1:19-cv-00741?
Short answer: Not determinable from the information provided.
Typical entry-risk gating items
Even after filing:
- a stay under 30-month provisions can delay effective approval,
- a final judgment can remove barriers,
- settlement terms can create an agreed entry runway.
No filing dates, stay order details, or injunction/consent terms are included in the provided information.
Which companies are challenging OSI’s product portfolio alongside Zydus?
Short answer: Not determinable from the information provided.
Co-defendants and parallel litigations
Competitors often file other Paragraph IV actions against the same Orange Book set. Without the drug identity and related docket list, parallel challenges cannot be mapped.
What is the procedural posture as of now?
Short answer: Not determinable from the information provided.
Docket states that matter for decision-making
Business and litigation teams track:
- motion to dismiss/claim construction schedule,
- summary judgment deadline,
- trial date or pretrial conference,
- whether there is a stipulation of dismissal,
- whether an appeal was filed.
No docket timeline events are provided here.
Key Takeaways
- OSI Pharmaceuticals, LLC v. Zydus Pharmaceuticals (USA) Inc., 1:19-cv-00741, is a Hatch-Waxman style patent infringement dispute initiated in 2019 by OSI against Zydus.
- The case is patent-centric, but the asserted patent numbers, claim scope, and decision outcomes are not provided in the input.
- A litigation outcome and patent-estate strength assessment cannot be completed without asserted-patent identifiers and docket rulings.
FAQs
-
What type of lawsuit is OSI Pharmaceuticals v. Zydus 1:19-cv-00741?
A Paragraph IV Hatch-Waxman patent infringement action is the expected structure under the case identifier, but specific counts and statutory bases beyond that cannot be confirmed from the provided input.
-
Which Orange Book patents triggered OSI’s filing?
Not determinable from the information provided.
-
What happens to FDA approval timing when a Paragraph IV case like this is filed?
Hatch-Waxman litigation can trigger a 30-month stay and/or other timing constraints, but specific stay and approval effects for this case are not provided here.
-
Does a settlement in a Hatch-Waxman case allow generic entry immediately?
Sometimes, depending on the settlement terms, agreed design, and entry dates, but settlement terms for this case are not provided.
-
Can Zydus design around asserted claims and still launch?
Design-around pathways exist in theory, but whether they were used, adjudicated, or accepted in this matter is not provided.
References
- United States District Court docket: OSI Pharmaceuticals, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:19-cv-00741.
